Clear All
11888 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
67457-0530-35 67457-0530 LEUCOVORIN CALCIUM LEUCOVORIN CALCIUM 350.0 mg/17.5mL Ancillary Therapy Chemoprotective Antidote Intramuscular, Intravenous Jan 2, 2019 In Use
36000-0012-05 36000-0012 Ondansetron Hydrochloride Ondansetron Hydrochloride 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Mar 13, 2013 May 10, 2013 No Longer Used
63187-0513-30 63187-0513 ondansetron hydrochloride Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec 1, 2018 In Use
43063-0052-02 43063-0052 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan 16, 2010 Aug 20, 2018 No Longer Used
65862-0187-03 65862-0187 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jul 31, 2007 In Use
00069-1318-04 00069-1318 epoetin alfa-epbx RETACRIT 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Dec 1, 2020 In Use
55513-0014-01 55513-0014 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Oct 1, 2001 Feb 28, 2009 No Longer Used
35356-0679-30 35356-0679 ONDANSETRON HYDROCHLORIDE ONDANSETRON HYDROCHLORIDE 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 25, 2007 Jun 30, 2019 In Use
55513-0015-01 55513-0014 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Aug 19, 2002 Apr 30, 2009 No Longer Used
54569-5873-02 54569-5873 Ondansetron, ondansetron hydrochloride Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 4, 2016 In Use
61919-0465-10 61919-0465 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan 1, 2014 In Use
68788-8582-05 68788-8582 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb 12, 2024 In Use
65293-0373-25 65293-0373 ONDANSETRON HYDROCHLORIDE Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Nov 18, 2009 Jan 31, 2015 In Use
51407-0701-05 51407-0701 APREPITANT APREPITANT 40.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Jun 11, 2025 In Use
62756-0356-66 62756-0356 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug 2, 2007 In Use
70934-0809-83 70934-0809 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Apr 22, 2021 Feb 28, 2025 No Longer Used
63187-0199-10 63187-0199 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct 1, 2014 In Use
70518-2363-05 70518-2363 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Jan 11, 2022 In Use
70518-3512-03 70518-3512 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct 31, 2023 Nov 24, 2024 In Use
66116-0604-05 66116-0604 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jul 31, 2007 In Use
00409-4755-01 00409-4755 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Nov 2, 2006 Apr 1, 2009 In Use
69339-0171-05 69339-0171 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct 24, 2022 In Use
69315-0185-12 69315-0185 Leucovorin calcium Leucovorin calcium 10.0 mg/1 Ancillary Therapy Chemoprotective Antidote Oral Nov 16, 2020 In Use
00006-4121-02 00006-4121 Human Papillomavirus 9-valent Vaccine, Recombinant GARDASIL 9 40.0 ug/.5mL, 60.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 30.0 ug/.5mL Ancillary Therapy Protective Agent HPV Vaccine Intramuscular Dec 10, 2014 In Use
51655-0196-53 51655-0196 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jul 20, 2022 In Use

Found 11888 results — Export these results